BCG Treatment for Bladder Cancer

This trial explores whether patient positioning during bladder cancer treatment with BCG affects the duration the medication stays in the bladder. BCG is a common treatment for non-muscle invasive bladder cancer. Researchers aim to determine if sitting, lying down, or having no restrictions can enhance its effectiveness by prolonging its presence in the bladder. This study is particularly relevant for patients with limited bladder capacity or severe urinary symptoms. Ideal participants include those with intermediate or high-risk bladder cancer who have not started BCG treatment and can maintain different positions for up to two hours. Participants will wear a fitness tracker to monitor activity. As a Phase 4 trial, this research seeks to understand how an already FDA-approved and effective treatment can benefit more patients.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that Bacillus Calmette-Guerin (BCG) therapy is generally safe for treating bladder cancer that hasn't spread into the muscle. Studies have found that BCG treatment reduces the chances of cancer recurrence or progression. Patients typically tolerate BCG well, especially compared to treatments like anti-PD-1/PD-L1 therapies, which often cause more side effects.

Researchers are excited about the BCG treatment for bladder cancer because it explores different patient positions during treatment, which is not standard in current care. While standard BCG therapy involves intravesical administration without specific positional guidance, this trial investigates whether lying down or sitting might enhance treatment efficacy. Additionally, the use of a Fitbit activity tracker provides new data on how physical activity post-treatment might impact outcomes, offering fresh insights that could refine future bladder cancer therapies.

Research has shown that the Bacillus Calmette-Guérin (BCG) vaccine effectively treats a type of bladder cancer that hasn't spread into the muscle. Studies consistently find that BCG reduces the chance of cancer recurrence and helps prevent progression. Specifically, BCG treatment can eliminate cancer in about 70% of patients with carcinoma in situ, a cancer confined to the bladder lining. It is considered the best treatment for this type of bladder cancer. However, about 40% of patients may still experience cancer recurrence after treatment. Despite this, BCG remains the most effective option for patients at high risk. In this trial, participants will receive BCG treatment with different post-treatment activity guidance to evaluate its impact on treatment effectiveness.¹⁶⁷⁸⁹